Monitor for future announcements on clinical trial initiation or additional manufacturing scale-up orders, which could signal growing commercial potential and provide upside to Lifecore’s CDMO revenue pipeline.
Price Chart
Executive Summary
Lifecore Biomedical (LFCR) has entered into a new development services agreement with Indomo to manufacture engineering and clinical batches of DT-001, a corticosteroid drug candidate for at-home treatment of inflammatory acne using Indomo's ClearPen™ self-injection device. This expands their existing collaboration and supports Indomo's planned Phase 2 clinical trials in 2026, highlighting Lifecore's growing role in autoinjector-based therapeutics beyond its traditional ophthalmic focus.
Key Facts
- Lifecore will produce engineering and clinical batches of DT-001 for Indomo’s acne treatment program.
- This is the second agreement between Lifecore and Indomo, expanding prior formulation and process optimization work.
- The drug candidate DT-001 is designed for use with Indomo’s investigational ClearPen™ intradermal self-injection device.
- Indomo aims to advance into Phase 2 clinical trials in 2026; the product is not yet FDA-approved.
- Acne affects 50 million Americans annually, but only 1 million receive corticosteroid injections due to limited dermatologist access.
Financial Impact
No financial terms disclosed; likely modest near-term revenue contribution from development services
Risk Factors
- Indomo’s program depends on successful Phase 2 trial outcomes and regulatory approval, which are uncertain.
- No disclosed financial value limits visibility into revenue impact for Lifecore.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249719 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $4.44 $4.74 | ▲ +6.76% | ▲ +7.36% | $6.53 (+47.07%) |
Jul 2, 2026 13w ago | 8-K | $5.09 $4.36 | ▲ +14.34% | ▲ +13.93% | $6.53 (−28.29%) |
Jun 15, 2026 15w ago | Press Release | $5.49 $4.63 | ▼ −15.66% | ▼ −14.91% | $6.53 (+18.94%) |
Jun 5, 2026 17w ago | 8-K | $5.57 $5.05 | ▼ −9.34% | ▼ −10.97% | $6.53 (+17.24%) |
Jun 2, 2026 17w ago | Press Release | $5.45 $5.27 | ▼ −3.30% | ▼ −1.74% | $6.53 (+19.82%) |
May 6, 2026 21w ago | 8-K | $4.96 $5.67 | ▼ −14.31% | ▼ −11.53% | $6.53 (−31.65%) |
Mar 26, 2026 27w ago | Press Release | $3.87 $5.02 | ▲ +29.72% | ▲ +19.05% | $6.53 (+68.73%) |
Mar 16, 2026 28w ago | Press Release | $4.37 $5.20 | ▲ +18.99% | ▲ +15.21% | $6.53 (+49.43%) |
Mar 4, 2026 30w ago | Press Release | $7.02 $3.84 | ▼ −45.30% | ▼ −41.51% | $6.53 (−6.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access